These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26349526)

  • 1. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
    Peter B; Winter GE; Blatt K; Bennett KL; Stefanzl G; Rix U; Eisenwort G; Hadzijusufovic E; Gridling M; Dutreix C; Hoermann G; Schwaab J; Radia D; Roesel J; Manley PW; Reiter A; Superti-Furga G; Valent P
    Leukemia; 2016 Feb; 30(2):464-72. PubMed ID: 26349526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.
    Krauth MT; Mirkina I; Herrmann H; Baumgartner C; Kneidinger M; Valent P
    Clin Exp Allergy; 2009 Nov; 39(11):1711-20. PubMed ID: 19860818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin: a magic bullet that blocks mast cell expansion and activation.
    Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J
    Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
    Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
    Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
    Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
    Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
    Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
    J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
    Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
    Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
    Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
    Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.
    Blatt K; Herrmann H; Mirkina I; Hadzijusufovic E; Peter B; Strommer S; Hoermann G; Mayerhofer M; Hoetzenecker K; Klepetko W; Ghanim V; Marth K; Füreder T; Wacheck V; Valenta R; Valent P
    PLoS One; 2012; 7(1):e29925. PubMed ID: 22299028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
    Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
    He H; Tran P; Gu H; Tedesco V; Zhang J; Lin W; Gatlik E; Klein K; Heimbach T
    Drug Metab Dispos; 2017 May; 45(5):540-555. PubMed ID: 28270565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antineoplastic efficacy profiles of avapritinib and nintedanib in
    Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
    Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
    Valent P; Akin C; Hartmann K; Reiter A; Gotlib J; Sotlar K; Sperr WR; Degenfeld-Schonburg L; Smiljkovic D; Triggiani M; Horny HP; Arock M; Galli SJ; Metcalfe DD
    J Allergy Clin Immunol; 2022 Jun; 149(6):1866-1874. PubMed ID: 35421448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCδ translocation in HMC-1(560) and HMC-1(560,816) cell lines.
    Tobío A; Alfonso A; Botana LM
    Immunopharmacol Immunotoxicol; 2015; 37(4):380-7. PubMed ID: 26181649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
    Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.